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Functional expression of a novel Kunitz
type protease inhibitor from the human
blood fluke Schistosoma mansoni
Shiwanthi L. Ranasinghe1,2*, Katja Fischer1, Geoffrey N. Gobert1 and Donald P. McManus1*
Abstract
Background: Schistosomes are able to survive for prolonged periods in the blood system, despite continuous
contact with coagulatory factors and mediators of the host immune system. Protease inhibitors likely play a critical
role in host immune modulation thereby promoting parasite survival in this extremely hostile environment. Even
though Kunitz type serine protease inhibitors have been shown to play important physiological functions in a
range of organisms these proteins are less well characterised in parasitic helminths.
Methods: We have cloned one gene sequence from S. mansoni, Smp_147730 (SmKI-1) which is coded for single
domain Kunitz type protease inhibitor, E. coli-expressed and purified. Immunolocalisation and western blotting was
carried out using affinity purified polyclonal anti-SmKI-1 murine antibodies to determine SmKI-1 expression in the
parasite. Protease inhibitor assays and coagulation assays were performed to evaluate the functional roles of SmKI-1.
Results: SmKI-1 is localised in the tegument of adult worms and the sub-shell region of eggs. Furthermore, this
Kunitz protein is secreted into the host in the ES products of the adult worm. Recombinant SmKI-1 inhibited
mammalian trypsin, chymotrypsin, neutrophil elastase, FXa and plasma kallikrein with IC50 values of 35 nM, 61 nM,
56 nM, 142 nM and 112 nM, respectively. However, no inhibition was detected for pancreatic elastase or cathepsin
G. SmKI-1 (4 μM) delayed blood clot formation, reflected in an approximately three fold increase in activated partial
thromboplastin time and prothrombin time.
Conclusions: We have functionally characterised the first Kunitz type protease inhibitor (SmKI-1) from S. mansoni
and show that it has anti-inflammatory and anti-coagulant properties. SmKI-1 is one of a number of putative Kunitz
proteins in schistosomes that have presumably evolved as an adaptation to protect these parasites from the defence
mechanisms of their mammalian hosts. As such they may represent novel vaccine candidates and/or drug targets for
schistosomiasis control.
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Background
Despite constant contact with immune components in
the human blood system, adult schistosome worms
are capable of surviving for prolonged periods in the
mesenteric veins of humans, in some instances, more
than 30 years, without triggering host inflammatory
reactions or promoting thrombus (blood clot) formation
[1]. It has been demonstrated that a whole worm extract of
S. mansoni prolonged activated partial thromboplastin time
(APTT) and was able to specifically block the enzymatic ac-
tivation of factor XI (plasma thromboplastin antecedent;
PTA) by factor Xlla (activated Hageman factor) [2] but the
precise molecule(s) involved have not been identified. It is,
however, likely that schistosome protease inhibitors play a
role in interacting with the proteases involved in blood
coagulation. In general, parasitic helminths cause chronic
disease and have evolved remarkable capabilities to down
regulate host immunity, thereby ensuring their survival
within their mammalian hosts [3]. Activated mammalian
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leukocytes produce several substances including cationic
proteins, hydrolytic enzymes (mainly elastase and cathep-
sin G) and oxidants all of which can cause damage to
schistosomes. It is recognised that schistosomula, lung-
stage schistosomula, and adult worms are sensitive to both
pancreatic elastase and neutrophil elastase [4]. In turn, to
counteract the effects of elastase, schistosomes produce
protease inhibitors, the best example so far known being a
serpin, Smpi56 [5]. Kunitz type protease inhibitors also
possess the ability to inhibit several proteases, so their
functional characterisation is also important. On a prac-
tical level, it has been suggested that studies on protease
inhibitors can advance the understanding of host-parasite
biology and lead to the identification of novel vaccine can-
didates and/or drug targets against schistosomes [6].
The Kunitz type protease inhibitors are ubiquitous
in almost all eukaryotes [7–12], with bovine pancreatic
trypsin inhibitor (BPTI) being the first described [13].
These proteins possess one or more Kunitz domains, with
the Kunitz-type motif consisting of approximately 60 amino
acids, and having six conserved cysteine residues which
connect in a characteristic disulphide bonding pattern
(C1-C6, C2-C4, and C3-C5) [14]. The amino acid resi-
due at the P1 reactive site [15] is the major determinant
of the energetic and specificity of protease recognition
by Kunitz inhibitors; typical trypsin inhibitors contain
Arg (R) or Lys (K) at the P1 site whereas typical chymo-
trypsin inhibitors contain Leu (L) or Met (M) [16]. In
invertebrates, Kunitz inhibitors have been shown to be
involved in a range of physiological processes including
blood coagulation, fibrinolysis, inflammation and ion
channel blocking [17]. However, there is limited informa-
tion on the Kunitz inhibitors of parasitic helminths in
general [8, 18–20], and none on schistosomes, so that
functional characterisation of S. mansoni Kunitz proteins
may shed light on their role in the host-parasite interplay.
We identified several gene sequences encoding Kunitz
type protease inhibitors by interrogation of the available
genome sequence data for S. mansoni. Among these,
one gene (Smp_147730), having been previously shown
to be highly up-regulated in schistosomula by RNA-seq
transcriptome profiling [21] was selected and expressed
in E. coli and purified. This Kunitz inhibitor, designated
SmKI-1, is the first to be functionally characterised from
S. mansoni; it inhibits trypsin, chymotrypsin, neutrophil
elastase, FXa and plasma kallikrein, and prolongs both
APTT and prothrombin time (PT) for blood clot forma-




All animal experimentation was conducted in strict ac-
cordance with protocols approved by the QIMR Berghofer
Medical Research Institute (QIMRB) Animal Ethics
Committee (project number P242), which adheres to
the Australian code of practice for the care and use of
animals for scientific purposes, as well as the Queensland
Animal Care and Protection Act 2001; Queensland Ani-
mal Care and Protection Regulation 2002.
Parasite materials
The Puerto Rican strain of S. mansoni is maintained in
Animal Resource Centre (ARC) Swiss mice and Biompha-
laria glabrata snails at the QIMRB animal facility from
stocks provided by the Schistosomiasis Resource Centre,
Biomedical Research Institute, Rockville, Maryland, USA.
Biomphalaria glabrata snails were induced to shed by ex-
posure to bright light and cercariae were concentrated by
incubating the tubes in which they were contained on ice
for 0.5–1 h. Schistosomula were mechanically transformed
from cercariae using a standard protocol [22]. Adult
worms were perfused from ARC Swiss mice using sodium
citrate buffer (0.15 M sodium chloride, 0.05 M tri-sodium
citrate) 7 weeks after cercarial challenge and washed three
times with perfusion buffer to remove excess blood
products. S. mansoni eggs and miracidia were isolated
from infected mouse livers as described [23]. In brief,
collagenase B is used to degrade the interstitial matrix
of mouse liver tissue, after which the schistosome eggs
are separated from the liver cells by 2 single-step density
centrifugations through Percoll. Soluble parasite antigens
were prepared by homogenising adult worms, cercariae,
schistosomula, eggs and miracidia in PBS containing
1 mM EDTA and 1 mM PMSF on ice followed by centri-
fuging the homogenates at 16,000 g for 30 min at 4 °C. ES
products from adult worms were obtained following the
culture of S. mansoni worm pairs in perfusion buffer for
1 h at room temperature and subsequently collecting the
supernatants [24].
Cloning and expression of SmKI-1
Scrutiny of the S. mansoni genome, available at schistodb
(http://schistodb.net/schisto/), resulted in the identification
of several putative Kunitz type serine protease inhibitor
gene sequences. Among these, one gene, Smp_147730
(SmKI-1), had previously been shown to be highly up-
regulated in the transcriptomic profile of mechanically
transformed schistosomula [21] and was thus selected
for further characterisation. The amino acid sequence
for SmKI-1 was validated by confirming the presence of
start and stop codons, and SignalP 4.1 server [25] (http://
www.cbs.dtu.dk/services/SignalP/) was used to check for
the presence of a signal sequence. N-glycosylation site
prediction was carried out with NetNGlyc 1.0 Server
(http://www.cbs.dtu.dk/services/NetNGlyc/). Molecular
weight and isoelectric point calculations were per-
formed using the ExPASy-Compute pI/Mw tool (http://
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web.expasy.org/compute_pi/). The characteristic Kunitz
protein domain was identified by searching the PROSITE
database (http://prosite.expasy.org/) [26] and a multiple
sequence alignment of SmKI-1 with other putative
schistosome Kunitz proteins was generated with the
Clustal Omega program (http://www.ebi.ac.uk/Tools/msa/
clustalo/) [27]. Searches for similar protein sequences were
performed using BLAST (http://blast.ncbi.nlm.nih.gov/
Blast) on the NCBI (National Centre for Biotechnology In-
formation) web site. Phylogenetic analysis [28] was under-
taken using the putative S. mansoni Kunitz proteins and
several other functionally characterised Kunitz proteins
(http://phylogeny.lirmm.fr/phylo_cgi/index.cgi).
Primers with an introduced N-terminal 6 × His tag
were designed and produced by Sigma® Aldrich (forward
primer- 5ʹcatgccatggcacatcatcatcatcatcacgttagagacttgcattac
tcattgaatc3ʹ and reverse primer- 5ʹgatcctcgagctacacattgattc
tcattttacacactg3ʹ). The SmKI-1 gene sequence was ampli-
fied using cDNA from adult worms and MyTaq™ DNA
polymerase. Purified PCR products were digested with the
restriction enzymes NcoI and EcoRI and ligated into the
pET28a expression vector. The plasmid was transformed
into E. coli BL21 (DE3) cells and a positive recombinant
clone was grown in 5 ml of LB (Luria-Bertani) medium
containing 30 mg/ml Kanamycin as the starter culture.
Recombinant protein production was induced with 1 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) at mid-log
phase (A600 ~ 0.5-0.6) at 37 °C and samples were collected
after 4 h post-induction. Harvested induced cells were
lysed with lysozyme (10 mg/ml) in Tris buffer (100 mM
NaH2PO4, 10 mM Tris-Cl) and homogenised using a
Potter-Elvehjem homogeniser followed by sonication. In-
clusion bodies were collected by centrifugation at 12,000 g
for 20 min and then washed three times with Tris buffer
containing 0.5 % (v/v) Triton-X 100. Inclusion bodies,
solubilised in 6 M GuHCl, were allowed to bind to Ni
charged resin (Novagen, Madison, WI, USA) at 4 °C. The
flow through was collected and then the Ni column was
washed sequentially three times with 4 ml Tris buffer con-
taining 40 mM, 50 mM and 70 mM imidazole. Then,
50 ml of elution buffer (50 mM NaH2PO4, 300 mM NaCl),
without imidazole, were allowed to pass through the
column and, finally, refolded protein was eluted with
the elution buffer containing 250 mM imidazole. The
recombinant (r) SmKI-1 protein was electrophoresed
on 15 % (w/v) sodium dodecyl sulphate polyacrylamide
gels and its protein concentration determined using the
Bradford assay [29].
Real time PCR
Preparations of cDNA from adult male and female worms,
eggs, miracidia, cercariae and newly transformed schistoso-
mula were used for real time PCR. Real time PCR was
performed using SYBR Green master mix (Applied
Biosystems) on a Corbett Rotor Gene 6000 thermal cy-
cler (Corbett Life Sciences). DNA segregation ATPase
(TC15682 - Smp176580, Contig809759.1) [30] was used as
the housekeeping gene for normalisation of the data. Each
cDNA sample (25 ng per reaction) was tested in quadrupli-
cate using forward (5ʹ tggtgaggaaactcggagac 3ʹ) and reverse
(5ʹ cttccaaaatggccgtga 3ʹ) primers. All real time PCR re-
actions were carried out in duplicate, the confidence
threshold (CT) of the second set of the results being
normalised to the first set before evaluation. This was
done by importing the standard curve of the first set to
the second using Rotor-Gene 6000 software.
Western blotting and immunolocalisation
Antigen affinity purified polyclonal antibodies against
rSmKI-1 were custom made in mice by GenScript
(Piscataway, NJ, USA). To test the specificity of the
anti-rSmKI-1 antibodies, western blotting was first carried
out with SmKI-1, BPTI (Roche diagnostics, Mannheim,
Germany), E. coli expressed Echinococcus granulosus Kunitz
protein (EgKI) (GenBank: EUB57880.1) and ulinastatin
(human urinary trypsin inhibitor) which is composed
of two Kunitz-type domains and functions as an anti-
inflammatory compound (Prospec-Tany TechnoGene
Ltd, Ness Ziona, Israel). rSmKI-1 and the other Kunitz
proteins were separated on a 15 % (w/v) SDS-PAGE gel
and transferred to an Immun-Blot® low fluorescence-PVDF
membrane. Overnight blocking was performed with Odys-
sey buffer at 4 °C. Then, the membrane was subjected to in-
cubation with the mouse anti-SmKI-1 anti-serum (1:2,000
dilution in Odyssey buffer and 0.1 % Tween-20) for one
hour followed by incubation with IRDye-labeled 680LT goat
anti-mouse antibody (1:15,000 diluted in Odyssey buffer
with 0.1 % Tween-20 and 0.01 % SDS) for one hour on a
shaker in a dark chamber. After a final wash with distilled
water, the membrane was allowed to dry in the dark and
visualised using the Odyssey® CLx Infrared Imaging System.
Western blotting was also carried out using S. mansoni ES
products and soluble adult antigens with the specific anti-
SmKI-1 antibodies.
Tissue sections (4 μm) were adhered onto charged
adhesive microscope slides from paraffin blocks of adult
worms and mouse liver sections with trapped eggs. Follow-
ing de-paraffinisation and rehydration, antigen retrieval was
done with RevealtA solution (Biocare Medical, Concord,
CA, USA). Then the tissue sections were blocked with 1 %
(v/v) bovine serum albumin in TBS for 1 h at RT in a
humidified chamber and incubated with anti-SmKI-1
antibodies (1:200) at 4 °C overnight. After three washes
with TBS-T, the sections were incubated with Alexa
fluor® 488 donkey anti-mouse IgG (1:500) (Invitrogen,
Carlsbad, CA, USA) at 37 °C for 1 h. Nuclei in the tissue
sections were counterstained with DAPIgold® (Invitrogen,
Carlsbad, CA, USA) and observed under an EVOS®
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fluorescence microscope. Whole parasite mounts were also
performed to check SmKI-1 protein expression in cercariae,
schistosomula and miracidia, as described [31]. Briefly, the
S. mansoni samples were fixed in 1.5 ml tubes with 4 %
(v/v) phosphate buffered formalin for 25–30 min and
then pelleted by a brief (~10-15 s) spin in an Eppendorf
5810R centrifuge (Hamburg, Germany) with brake set-
tings on 0 or 1. Fixed samples were then permeabilised
by rinsing three times with PBSTx (PBS with 0.3 % Triton
X-100) and incubated in blocking solution (1 % BSA and
0.05 % Tween-20 in PBSTx) for 1.5-2 h. The subsequent
steps were carried out as described for the paraffin block
sections.
Anti-coagulation and protease inhibition activity of
SmKI-1
To test whether or not the blood coagulation pathways
were functional, in the presence of rSmKI-1, three stan-
dardised tests, the activated partial thromboplastin time
(APTT), the prothrombin time (PT) and the thrombin
clotting time (TCT), were performed. These tests are
widely used to determine anti-coagulation property of
human blood [32]. APTT determines the deficiencies of
intrinsic and common blood coagulation pathways, PT
of extrinsic and common pathways, whereas TCT detects
fibrinogen related disorders [32]. Plasma was separated
from fresh human blood collected into sodium citrate
vacutainers and incubated with different concentrations of
SmKI-1 for 10 min in a 37 °C water bath. After adding
CaCl2 to the mixture, the time taken for clot formation
was measured by a Sta-R coagulometer (Diagnostica stago,
Asnières sur Seine Cedex, France). TriniCLOTTM APTT
HS (Trinity Biotech, Bray, Co.Wicklow, Ireland), Throm-
borel®S (Siemens, Munich, Bavaria, Germany) and STA®-
Thrombin (Diagnostica stago, Asnières sur Seine Cedex,
France) kits were used for the determination of the APTT,
PT [33–35] and TCT [36], respectively. Aprotinin and
FVII negative plasma (Diagnostic Grifols, S.A., Spain)
were used as the positive controls for APTT, TCT and
PT, respectively. All tests were performed on two separate
occasions each time using duplicate samples.
The protease inhibitor activity of rSmKI-1 was tested
using a range of commercially available mammalian
proteases: bovine trypsin, bovine chymotrypsin, porcine
pancreatic elastase (PPE), human neutrophil elastase
(HNE), human cathepsin G, activated coagulation factor X
(FXa) and plasma kallikrein (PK). Each protease was incu-
bated in the presence or absence of the rSmKI-1 protein in
96 well plates for 10 min. Then a chromogenic or fluoro-
genic substrate was added at concentrations ranging from
100 mM to 5 μM and the product formed was measured
using a POLARstar OPTIMA microplate reader (BMG Lab
Tech, Mornington, VIC, Australia) every min for 30 min.
Bovine pancreatic trypsin, bovine pancreatic α-chymo-
trypsin and the fluorogenic substrates Nα-Benzoyl-L-ar-
ginine-7-amido-4-methylcoumarin hydrochloride and
N-Succinyl-Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin
were purchased from Sigma Aldrich (St Louis, MO, USA).
Trypsin and chymotrypsin assays were performed in
200 mM Tris–HCl (pH 8.2) containing 20 mM CaCl2
and 0.1 % (w/v) PEG 8000 at 37 °C. The kinetic rate of the
substrate hydrolysis was measured at excitation/emission
wavelengths of 370/460 nm. The activity of PPE was
observed using the Enzcheck® elastase assay kit (Life
technologies, Carlsbad, CA, USA) following the manufac-
turer’s instructions. Fluorescence signals were measured
at 505/515 nm. HNE (SE284-0100) and Cathepsin G
(SE283-0100), with the corresponding substrates N-Meth-
oxysuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin
(P224-0005) and Suc-Ala-Ala-Pro-Phe-pNA (P141-0025)
respectively, were purchased from Enzolifesciences (NY,
USA). The HNE assay was carried out with a buffer con-
taining 100 mM HEPES, 300 mM NaCl and 0.05 % (v/v)
Tween-20 (pH 8) at 25 °C with 2.5 nM enzyme and fluor-
escence signals were detected at 370/460 nm. Cathepsin G
activity was measured in 100 mM Tris–HCl, 1.6 M NaCl
buffer (pH 7.5) with 100 nM enzyme at 25 °C and the re-
lease of Pro-Phe-pNA was measured at 405 nm.
An activated Factor X inhibitor assay kit (Biovision
Inc., Milpitas, CA, USA) was used to determine the inhibi-
tory effect of rSmKI-1 on FXa and the fluorescence signals
were detected at 350/450 nm. Human plasma kallikrein
and fluorogenic kallikrein substrates (EMD Millipore,
Billerica, MA, USA) were used to test for kallikrein ac-
tivity in the presence or absence of rSmKI-1. Substrate
hydrolysis was determined at 400/505 nm.
The values were corrected after subtracting background
signals and all experiments were performed in triplicate.
Results were expressed as a percentage of the relative
inhibitory activity of the rSmKI-1 protein using the
formula:
Percentage of relative activity
¼ ΔRFU of rSmKI−1= ΔRFU of enzyme controlð Þ x 100%
Δ Relative unit (RU) = R2 - R1, Readings R1 and R2
were taken at t1 and t2 time points respectively, when
the reaction was in the linear range. The half maximal
inhibitory concentration (IC50) values were calculated




Sequence searches revealed the presence of seven putative
Kunitz proteins in S. mansoni (Additional file 1). One
contained two (Smp_052230) Kunitz domains while the
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remaining Kunitz molecules were associated with other
domains such as chitin binding type-2 (Smp_180810)
or spondin (Smp_180240), with Smp_180240 having
two distorted Kunitz domains. The Kunitz domain of
Smp_147710 did not contain the characteristic inhibitory
amino acid at the P1 site and probably has an alternative
function to protease inhibition. Two amino acid sequences
with a single Kunitz domain (Smp_179120 and Smp_139
840) were each devoid of two essential cysteine residues.
Smp_147730 (SmKI-1 - Gene bank accession number
CCD77156) was selected for further characterisation as it
had a single secretory type Kunitz protein domain contain-
ing the inhibitory amino acid at the P1 site and was of full
length. Furthermore, the Smp_147730 gene had been
shown previously to be highly expressed in mechanically
transformed S. mansoni schistosomula [21]. Clustal align-
ment (Fig. 1) of the Kunitz domains of these putative S.
mansoni Kunitz proteins and BPTI showed that the amino
acid sequence is highly conserved within the domain.
Smp_180240 was excluded due to its two highly distorted
Kunitz domains.
SmKI-1 is comprised of 146 amino acids and has a signal
peptide of 20 residues. The mature protein has a putative
molecular mass of 15.108 kDa and an isoelectric point of
8.22. One putative N-glycosylation site is predicted for the
mature SmKI-1 protein. Phylogenetic analysis (Fig. 2) with
SmKI-1 and other functionally characterised Kunitz
proteins revealed a high relatedness of SmKI-1 with
Simukunin, a Kunitz type plasma coagulation inhibitor
from the salivary glands of the black fly Simulium vittatum
[37]. BLASTP analysis revealed that SmKI-1 shared greatest
sequence identity (63 % identity and 34 % query cover, E
value 2x10−21) with Simukunin. SmKI-1 had the second
highest sequence identity (57 % identity and 39 % query
cover, E value 5x10−18) with human tissue factor pathway
inhibitor-2 (TFPI-2) (GenBank No AAA20094.1), which is
a three tandem domain Kunitz protein.
SmKI-1 gene expression
Real time PCR on preparations of cDNA from a range of
S. mansoni life cycle stages indicated that the SmKI-1
gene was highly expressed in both male and female adult
worms but no expression was evident in miracidia, cer-
cariae, schistosomula or eggs (Fig. 3).
Protein purification and western blotting
A yield of 1.1 mg/ml recombinant SmKI-1 protein was
obtained with ≥85 % purity from 800 ml total culture
volume. The mouse anti-SmKI-1 polyclonal antibody was
shown to be specific as no cross reactivity with other tested
Kunitz proteins was evident (Fig. 4). Western blotting using
this antibody to probe a whole soluble parasite antigen
extract and ES products of adult S. mansoni revealed
the presence of a low level of SmKI-1 but only in the
ES products (not shown).
Localisation of SmKI-1
Immunolocalisation, using the mouse polyclonal anti-
SmKI-1 anti-serum, indicated the presence of SmKI-1
along the tegument of adult worms, specifically in the
tubercles of males and in the sub-shell region of eggs
trapped in infected liver tissue (Fig. 5). No immunoreac-
tivity was evident with cercariae, schistosomula or mira-
cidia (data not shown).
Coagulation assays
Recombinant SmKI-1 extended blood coagulation time
in a dose dependent manner; i.e. in the presence of in-
creasing rSmKI-1 concentrations clot formation was de-
layed in both the APTT and the PT (Fig. 6). The normal
time period for clot formation in APTT is 26–41 s and
in PT is 10–14 s. An approximately three-fold increase
in the time taken for clot formation was observed in
both assays when rSmKI-1 was present at a concentra-
tion of 4 μM. The prolongation in time of both APTT
and PT suggests that SmKI-1 inhibits one or more of the
coagulation factors involved in the intrinsic, extrinsic or
common coagulation pathways. No direct thrombin in-
hibition was detected as clot formation was completed
within the normal time period of 12–18 s for TCT (data
not shown) which ruled out any interference of SmKI-1
with the conversion of fibrinogen to fibrin. Notably,
Fig. 1 Clustal alignment of the Kunitz domains of Smp_147710, Smp_179120, Smp_139840, Smp_147730 (SmKI-1), the 1st Kunitz domain of
Smp_052230, the 4th and 6th Kunitz domains of Smp_180810 and BPTI. The six conserved cysteine residues are highlighted in black, the P1 site is
shown by the black arrow head and the Kunitz family signature is shown as the double headed arrow
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SmKI-1 inhibited two tested coagulation associated
serine proteases, FXa and plasma kallikrein, in the
nanomolar range (Fig. 7).
Protease inhibition assays
Purified rSmKI-1 inhibited trypsin, chymotrypsin, neu-
trophil elastase, FXa and plasma kallikrein with IC50
values of 35 nM, 61 nM, 56 nM, 142 nM and 112 nM
respectively (Fig. 7), but had limited or no effect on ca-
thepsin G or pancreatic elastase (data not shown). The
results indicate that SmKI-1 is a potent trypsin inhibitor
which is in agreement with the published literature that
Kunitz proteins containing Arg at the P1 site are typical
trypsin inhibitors. The inhibition of FXa and plasma kal-
likrein further supports the ability of SmKI-1 to inhibit
blood coagulation and the inhibition of neutrophil elastase
indicates its capability to interfere with inflammatory
reactions.
Discussion
Proteases play important roles in a variety of biological
processes in higher animals, including immune defense,
inflammation, blood clotting and tissue remodeling [38].
Serine proteases represent over one third of the known
proteolytic enzymes and the Clan PA proteases, bearing
the trypsin fold, are the largest family; most Clan PA
proteins have trypsin-like substrate specificity and are
involved mainly in blood coagulation and the immune
response [39]. Neutrophils are the first line of defence in
human innate immunity [40]. Recent findings suggest
that neutrophil elastase, secreted by activated neutro-
phils, triggers inflammatory reactions as well as the initi-
ation of blood coagulation by inducing the secretion of
tissue factor [41] and inhibiting tissue factor pathway in-
hibitor (TFPI) [42]. Here we show that SmKI-1 inhibits
several proteases, including neutrophil elastase, which is
involved in triggering immune response reactions. Tryp-
sin and chymotrypsin are serine protease digestive en-
zymes which degrade proteins in the small intestine.
Secretion of SmKI-1 by schistosome eggs might indicate
it has an additional function in providing protection
from these proteolytic enzymes in the gut as many eggs
traverse the intestinal wall and pass into the gut lumen
prior to being excreted in human stool to the external
environment.
The presence of the male and female worm pairs in
the mesenteric veins of the small intestine host blood
vessels leads to hypercoagulability through alterations in
blood flow and endothelial function [43]. This feature
and the negatively charged surface of schistosomes
would be expected to trigger the activation of molecules
involved in initiating blood coagulation. Worm pairs
cause local anti-thrombogenic effects while the presence
of eggs causes systemic effects [44]. However, the hypo-
coagulable and hyperfibrinolytic state of hepatosplenic
schistosomiasis patients indicates that schistosomes are
capable of suppressing the host haemostatic response
and, preventing thrombus formation [43]. Factor XII in
blood is activated when exposed to a negatively charged
surface, such as that presented by S. mansoni, which then
triggers the intrinsic coagulation pathway. A cascade of re-
actions subsequently leads to the activation of the com-
mon coagulation pathway which ultimately results in the
formation of a fibrin clot [44]. We show here that SmKI-1
can inhibit the proteolytic activities of coagulation factor
Xa, also known as prothrombinase, thrombokinase or
thromboplastin, and plasma kallikrein, another serine pro-
tease involved in coagulation that generates plasmin from
plasminogen and liberates kinins from kininogens. The in-
hibition of FXa and plasma kallikrein in the nanomolar
range and prolongation of the APTT and PT by SmKI-1
suggests this Kunitz protein likely plays a role in interfer-
ing with the mammalian host coagulation pathways. Even
Fig. 2 Phylogenetic analysis of SmKI-1 and functionally characterised
Kunitz proteins from other taxa: Simukunin (ACH56928.1) from the
blackfly Simulium vittatum, EgKU8 (ACM79010.1) from Echinococcus
granulosus, Fh-KTM (AAB46830.1) from Fasciola hepatica, Ixolaris
(AAK83022.1) from the hard-tick Ixodes scapularis, BPTI (1510193A)
and human TFPI-2 (AAA20094)
Fig. 3 Real time PCR showing expression of the SmKI-1 gene after
normalisation with DNA segregation ATPase as housekeeping
gene. The error bars represent the mean ± standard error of the
mean (SEM)
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though a relatively high concentration of SmKI-1 (micro-
molar range) was needed for a visible positive reaction in
the coagulation assays we performed, the observed inhib-
ition of PK and FXa in the nanomolar range suggests that
a lower concentration of SmKI-1 would result in an effect-
ive level of anti-coagulant activity in vivo.
It has long been documented that the excretory-
secretory (ES) products of the parasitic worms can
modulate the expression of host immune responses [45].
Schistosome ES products, which act at the interface be-
tween these blood flukes and the mammalian host, may
be responsible for the capacity of schistosomes to redirect
Fig. 4 SDS-PAGE (left panel) (3 μg of each protein) and Western blotting (300 ng of each protein) with mouse anti-SmKI-1 polyclonal antibody
(right panel): Lane 1, ulinastatin; lane 2, SmKI-1; lane 3, EgKI; lane 4, BPTI; M, Molecular weight markers (kDa)
Fig. 5 Immunolocalisation of SmKI-1 in adult male S. mansoni (a), adult female S. mansoni (b) and S. mansoni eggs (white arrows) trapped
in infected liver tissue (c): (i). with white light; (ii). with anti-SmKI-1 antibodies and (iii) with negative control pre-immune mouse serum.
Positive immunofluorescence for SmKI-1 is shown in green and the nuclei stained with DAPI appear blue. (Scale bar = 200 μm)
Ranasinghe et al. Parasites & Vectors  (2015) 8:408 Page 7 of 10
the host immune system, thereby modulating the immune
response [46]. Recent advances in genomics, transcripto-
mics and proteomics have shown that these ES products
contain soluble mediators which ligate, degrade or interact
with host immune cells [47, 48]. Helminth ES products
predominantly consist of proteases, protease inhibitors,
venom allergen homologues, glycolytic enzymes and
lectins [46]. Even though the qPCR showed high mRNA
expression of SmKI-1, low protein expression was evident
in adult ES products. Several possible reasons have been
discussed previously for the poor correlation between the
levels of mRNA and protein expression, the main one being
the complicated and variable post-translational mechanisms
involved [49, 50]. SmKI-1 may be secreted as a response to
an external stimulus such as the presence of a protease.
With in vitro experiments it is difficult to determine precise
mechanisms taking place in vivo. It is noteworthy, however,
that SmKI-1 has not been identified in recent reports of the
S. mansoni proteome [51–53]. Proteomic studies generally
identify the most abundant ES proteins but they may
miss those that are bioactive but which are present at a
low level [46].
The outer surface of the adult schistosome tegument
is a unique double membrane structure which plays a
crucial role in modulating host responses and ensuring
parasite survival [54]. As a tegumentally localised protein,
released in the ES, we propose that SmKI-1 is intimately
involved in providing protection to the parasite in its
mammalian host. Resident in mesenteric veins, schisto-
somes release eggs into the blood circulation where
they are also exposed to host attack. This may stimulate
the eggs to produce and secrete biologically important
proteins such as SmKI-1, which can provide protection
from the immune system. In support of this, we have
shown by immunolocalisation that SmKI-1 is present
between the outer shell and the developing miracidia in
eggs trapped in the infected mouse liver. However, there
was no immunoreactivity of polyclonal anti-SmKI-1 anti-
bodies with purified, isolated eggs or soluble egg antigens
(SEA) obtained from the purified eggs of S. mansoni. Nei-
ther were we able to detect SmKI-1 gene expression in the
purified eggs by real time PCR. A possible reason could be
that mRNAs of some genes are less stable than proteins
[55] and the extensive, time consuming collagenase-based
procedure we used to purify S. mansoni eggs from infected
mouse livers likely caused the inhibition of SmKI-1 mRNA
expression. In addition, the SmKI-1 protein could have
been washed away during the purification procedure. In
contrast, fixing infected liver tissue soon after it was
obtained, likely preserved the integrity of SmKI-1 and
its expression in eggs trapped in the liver tissue.
The Smp_147730 gene, encoding the Kunitz inhibitor
characterised here, was previously identified following
transcriptome profiling of mechanically transformed, but
not skin transformed, S. mansoni schistosomula [21].
Depending on which cercarial transformation method is
used, RNA transcription and protein expression can vary
[56]. The method we used in this study to transform
schistosomula was different from the earlier method
used [21] which might explain why we did not observe
upregulation of the SmKI-1 gene in schistosomula. In
this context, it is noteworthy that significant differences
in gene expression profiles have also been reported be-
tween mechanically transformed and in vivo obtained lung
schistosomula of S. japonicum have also been reported
[57]. It is likely that schistosomula transiently express and
secrete key proteins, including SmKI-1, soon after skin
penetration, in order to survive host immune attack.
Schistosomes exhibit remarkably diverse mechanisms
to regulate their interactions with the mammalian host
and often use molecular mimicry [58]. TFPI is a naturally
occurring coagulation inhibitor which regulates the hu-
man coagulation pathway. It is also a Kunitz type protein
containing three domains with dual inhibitory actions
whereby it binds to the tissue factor/FVIIa complex to
prevent it from acting on FIX and FX substrates as well as
Fig. 6 SmKI-1 prolongs both APTT and PT in clot formation. The
normal time periods for clot formation during APTT and PT are
shown by the rectangles. Aprotinin and FVII-deficient plasma were
used as positive controls for APTT and PT, respectively. Error bars
represent the mean ± SEM
Fig. 7 Percentage of relative inhibitory activity of rSmKI-1 against
trypsin, chymotrypsin neutrophil elastase, FXa and plasma kallikrein.
Error bars represent means ± SEM; [I], concentration of rSmKI-1
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directly inhibiting FXa [59]. Having high sequence similar-
ity to TFPI, SmKI-1 may have evolved to mimic the func-
tions of this human Kunitz protein.
Conclusion
Our characterisation of SmKI-1 suggests that this Kunitz
protein likely plays a specific and essential biological role
in protecting the fluke from the onslaught of the host
defenses through the inhibition of serine proteases in-
volved in coagulation and inflammation, and may therefore
be a good candidate for future evaluation as a vaccine or
drug target. Moreover, its inhibition of FXa and plasma
kallikrein and the prolongation of blood clotting time point
towards the potential clinical application of SmKI-1 in
anti-thrombotic therapy. Further studies are needed to
characterise the other putative Kunitz inhibitors we have
identified in order to further increase our knowledge of
schistosome defense mechanisms.
Additional file
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